Evidence map›Paper›PMID 33847940›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2021

Detection of C3 Nephritic Factor by Hemolytic Assay.

Melchior Chabannes, Véronique Frémeaux-Bacchi, Sophie Chauvet

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Acquired drivers of C3 glomerulopathy.Clinical kidney journal · 2025
    Review
  2. Alternative pathway diagnostics.Immunological reviews · 2023
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Melchior ChabannesINSERM, UMR_S 1138, Inflammation, Complement and Cancer Team, Centre de Recherche des Cordeliers, Sorbonne Universités, Université de Paris, Paris, France.
Véronique Frémeaux-BacchiINSERM, UMR_S 1138, Inflammation, Complement and Cancer Team, Centre de Recherche des Cordeliers, Sorbonne Universités, Université de Paris, Paris, France.
Sophie ChauvetINSERM, UMR_S 1138, Inflammation, Complement and Cancer Team, Centre de Recherche des Cordeliers, Sorbonne Universités, Université de Paris, Paris, France. sophie.chauvet@aphp.fr.
Sorbonne Université · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

C3 nephritic Factor (C3NeF) is autoantibody that binds neoepitopes of the C3 convertase C3bBb, resulting in a stabilization of the enzyme. First functional characterizations of C3NeF were performed by hemolytic assays using preactivated sheep erythrocytes (bearing C3b). Sheep erythrocytes are beforehand sensitized with an anti-sheep red blood cell stroma antibody produced in rabbit (hemolysin). Sensitized sheep erythrocytes will initiate cascade complement activation via the classic pathway, followed by alternative pathway amplification loop, resulting in C3b covalent binding to cell surface. Sheep erythrocytes bearing C3b permit the alternative pathway exploration, in particular decay of alternative pathway C3 convertase.

Indexed as

AnimalsComplement ActivationComplement C3 Nephritic FactorComplement Hemolytic Activity AssayComplement Pathway, AlternativeErythrocytesGlomerulonephritisHemolysisHumansRatsSheepComplement C3 Nephritic FactorC3 glomerulopathyC3NefC3 Nephritic factor

Identifiers

PMID33847940
OpenAlexW3156542542

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.